Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14050265 | 0.76 | — | — | |
| SCHEMBL15833992 | 0.76 | — | — | |
| SCHEMBL7759973 | 0.76 | ALDH1A1 (0.41) | ALDH1A1TSHRSMN1; SMN2MAPTKMT2A | |
| SCHEMBL21096012 | 0.74 | — | — | |
| SCHEMBL9535834 | 0.74 | ALDH1A1 (0.59) | ALDH1A1TSHRSMN1; SMN2MAPTKMT2A | |
| SCHEMBL20254382 | 0.74 | ALDH1A1 (0.32) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL1389030 | 0.73 | TSHR (0.40) | ALDH1A1TSHRSMN1; SMN2MAPTKMT2A | |
| SCHEMBL4698983 | 0.73 | TSHR (0.40) | ALDH1A1TSHRSMN1; SMN2MAPTKMT2A | |
| SCHEMBL4698991 | 0.73 | ALDH1A1 (0.48) | ALDH1A1TSHRSMN1; SMN2MAPTKMT2A | |
| Iodide SCHEMBL8715117 | 0.71 | ALDH1A1 (0.37) | ALDH1A1TSHRSMN1; SMN2MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050191660-A1 | Labelled oligonucleotides synthesized on solid-supports | APPLERA CORPORATION (US) | 2005-09-01 | — | — | US | claimed |
| US-20030191303-A1 | Labelled oligonucleotides synthesized on solid-supports | APPLERA CORPORATION | 2003-10-09 | — | — | US | claimed |
| EP-1155027-B1 | SYNTHESIS OF LABELLED OLIGONUCLEOTIDES ON SOLID-SUPPORTS | APPLERA CORP (US) | 2003-10-01 | — | — | EP | claimed |
| US-6525183-B2 | Solid-support, a cleavable linker, moiety with >/= three attachment sites, a label, a nucleophile and an acid cleavable protecting group reacted in a cyclical fashion with a phosphoramidate protected nucleoside | PE CORPORATION (NY) | 2003-02-25 | — | — | US | claimed |
| US-20020165389-A1 | Multiple-labelled oligonucleotides synthesized on solid-supports | PE CORPORATION (NY) (US) | 2002-11-07 | — | — | US | claimed |
| EP-1155027-A2 | SYNTHESIS OF LABELLED OLIGONUCLEOTIDES ON SOLID-SUPPORTS | PE Corporation (NY) (US) | 2001-11-21 | — | — | EP | claimed |
| US-6316610-B2 | Hybrid stabilization | PE CORPORATION (NY) | 2001-11-13 | — | — | US | claimed |
| US-20010014735-A1 | Labelled oligonucleotides synthesized on solid-supports | PE CORPORATION (NY) | 2001-08-16 | — | — | US | claimed |
| US-6255476-B1 | REACTING A LABELLED SOLID SUPPORT OF GIVEN FORMULA TO REMOVE AN ACID CLEAVABLE PROTECTING GROUP, ADDING A 5'-PHOSPHORAMIDITE, 3'-PROTECTED NUCLEOSIDE AND AN ACTIVATOR TO FROM A BOND | PE CORPORATION (NY) | 2001-07-03 | — | — | US | claimed |
| WO-2000050432-A2 | SYNTHESIS OF LABELLED OLIGONUCLEOTIDES ON SOLID-SUPPORTS | PE CORPORATION (NY) (US) | 2000-08-31 | — | — | WO | claimed |
| EP-2276775-B1 | PROCESS FOR THE MANUFACTURE OF OLIGONUCLEOTIDES | NITTO DENKO AVECIA INC (US) | 2015-09-02 | — | — | EP | disclosed |
| US-8513404-B2 | Process for the manufacture of oligonucleotides | NITTO DENKO AVECIA, INC. (US) | 2013-08-20 | — | — | US | disclosed |
| WO-2012059510-A1 | BACK PRESSURE CONTROL DURING SOLID-PHASE SYNTHESIS ON POLYMERIC SUPPORTS | GIRINDUS AMERICA, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| US-20110087014-A1 | Process for the manufacture of oligonucleotides | GIRINDUS AMERICA, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| EP-2276775-A1 | PROCESS FOR THE MANUFACTURE OF OLIGONUCLEOTIDES | Girindus America, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| WO-1994024144-A2 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PURINES | GILEAD SCIENCES, INC. (US) | 1994-10-27 | — | — | WO | disclosed |
| EP-0616612-A1 | NUCLEASE STABLE AND BINDING COMPETENT OLIGOMERS AND METHODS FOR THEIR USE | GILEAD SCIENCES, INC. (US) | 1994-09-28 | — | — | EP | disclosed |
| WO-1993024508-A1 | BINDING COMPETENT OLIGOMERS CONTAINING 2', 5' LINKAGES | GILEAD SCIENCES, INC. (US) | 1993-12-09 | — | — | WO | disclosed |
| WO-1993012135-A1 | NUCLEASE STABLE AND BINDING COMPETENT OLIGOMERS AND METHODS FOR THEIR USE | GILEAD SCIENCES, INC. (US) | 1993-06-24 | — | — | WO | disclosed |
| WO-1993010820-A1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | GILEAD SCIENCES, INC. (US) | 1993-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191303-A1 | Labelled oligonucleotides synthesized on solid-supports | NSUN2, TST, NSUN3 | ALDH1A1 2059/4885TSHR 1581/4885SMN1; SMN2 726/4885 |
| US-20110087014-A1 | Process for the manufacture of oligonucleotides | RNGTT, RNMT, POLL | ALDH1A1 3736/4885TSHR 1566/4885SMN1; SMN2 829/4885 |
| US-20050191660-A1 | Labelled oligonucleotides synthesized on solid-supports | NSUN2, TST, STS | ALDH1A1 2944/4885TSHR 884/4885SMN1; SMN2 811/4885 |
| US-20020165389-A1 | Multiple-labelled oligonucleotides synthesized on solid-supports | NSUN2, NSUN3, RNGTT | ALDH1A1 2731/4885TSHR 1264/4885SMN1; SMN2 808/4885 |
| US-20010014735-A1 | Labelled oligonucleotides synthesized on solid-supports | NSUN2, TST, NSUN3 | ALDH1A1 2059/4885TSHR 1581/4885SMN1; SMN2 726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.